Do you want a global overview or region-specific details (e.g., US, EU, Asia), and what metric are you after (sales/market size, pricing, supply, regulatory status, or competitive landscape)?
Here’s a concise global snapshot to start:
- What is it: Losartan is an angiotensin II receptor blocker (ARB) used mainly to treat hypertension and certain kidney/heart conditions. It’s marketed as Cozaar (brand) and widely sold as a generic.
- Patent and market status: The original brand patents have expired in most markets, so losartan is now a heavily genericed product. Generics from many manufacturers have driven price competition and broad accessibility.
- Market dynamics:
- Generics dominate Losartan sales; price competition is intense, which typically keeps per-pill costs low.
- It’s one of the historically high-volume ARBs, but generic competition has reduced brand-name pricing and margins.
- Losartan sits in a large, ongoing class of antihypertensives (ARBs), which continues to see steady demand due to chronic hypertension management.
- Key considerations affecting the market:
- Safety/regulatory events: There have been NDMA impurity recalls in losartan lots in the past, leading to temporary supply disruptions and stricter quality testing. Such issues can impact short-term availability and sourcing.
- Competition within the ARB class: Other ARBs (valsartan, irbesartan, olmesartan, telmisartan) compete for the same patient population; prescribers may switch within the class based on price or formulation.
- Geographic variation: Pricing, generics availability, and supply stability vary by region. High-income markets tend to see strong generic competition and lower per-unit prices, while some emerging markets may have steadier demand but varying access.
- Formulation and dosing: Standard tablet strengths (e.g., 50 mg, 100 mg) and combination therapies influence market dynamics and prescribing patterns.
If you share the region and what you want to know (e.g., current annual market size, price ranges, supplier landscape, or regulatory status), I can tailor a more precise snapshot and pull in the latest data or reports.